García-Alfonso, PilarMuñoz, AndrésJiménez-Castro, JerónimoJiménez-Fonseca, PaulaPericay, CarlesLongo-Muñoz, FedericoReyna-Fortes, CarmenArgilés-Martínez, GuillemGonzález-Astorga, BeatrizGómez-Reina, María JoséRuiz-Casado, AnaRodríguez-Salas, NuriaLópez-López, RafaelCarmona-Bayonas, AlbertoConde-Herrero, VerónicaAranda, Enrique2024-02-192024-02-192021-09-08http://hdl.handle.net/10668/3928http://hdl.handle.net/20.500.12105/18457Trifluridine/tipiracil is currently approved for metastatic colorectal cancer (mCRC) refractory to available therapies. However, there is no consensus on factors that predict treatment outcomes in daily practice. We assessed the early clinical experience with trifluridine/tipiracil in Spain and potential survival markers. This was a retrospective cohort study of mCRC patients who participated in the trifluridine/tipiracil early clinical experience programme in Spain. The primary outcome was overall survival (OS). Associations between OS and patient characteristics were assessed using multivariate Cox regression analyses. A total of 379 patients were included in the study. Trifluridine/tipiracil was administered for a median of 3.0 cycles and discontinued mainly due to disease progression (79.2%). The median OS was 7.9 months, with a 12-month OS rate of 30.5%. Cox analyses revealed that the following variables independently enhanced OS: ≤2 metastatic sites, no liver metastasis, alkaline phosphatase < 300 IU, trifluridine/tipiracil dose reductions, and neutrophil/lymphocyte ratio < 5. Grade ≥ 3 toxicities were reported in 141 (37.2%) patients, including mainly afebrile neutropaenia (23.2%), anaemia (12.1%), and thrombocytopaenia (5.3%). This study supports the real-life efficacy and safety of trifluridine/tipiracil for refractory mCRC and identifies tumour burden, liver metastasis, alkaline phosphatase, dose reductions, and neutrophil/lymphocyte ratio as survival markers.engVoRBiomarkersChemotherapyColorectal cancerCombination therapyReal-lifeTrifluridine/tipiracilBiomarcadoresQuimioterapiaNeoplasias colorrectalesQuimioterapia combinadaTrifluridinaHumansTrifluridineAlkaline PhosphataseNeutrophilsRetrospective StudiesSpainTumor BurdenColorectal NeoplasmsNeutropeniaTreatment OutcomeDisease ProgressionRegression AnalysisThrombocytopeniaDigestive System NeoplasmsLymphocytesAnemiaAttribution 4.0 International3457274010.3390/cancers131845142072-6694Cancersopen access